Adagene (ADAG) Receivables (2019 - 2026)

Adagene (ADAG) posted quarterly Receivables of $7.5 million for Q4 2021, up 385.05% quarter-over-quarter from $1.5 million in Q2 2021.

Adagene (ADAG) Receivables (2019 - 2026) Analysis & Trends

Adagene (ADAG) has reported Receivables for 2 consecutive years, with $7.5 million the latest figure, recorded in Q4 2021.

In Q4 2021, Receivables changed N/A year-over-year to $7.5 million; the TTM figure through Dec 2021 stood at $7.5 million (changed N/A YoY), while the FY2021 annual figure was $7.5 million, changed N/A from the prior year.
Receivables rose to $7.5 million in Q4 2021 per ADAG's latest filing, from $1.5 million in the prior quarter.
Across five years, Receivables topped out at $7.5 million in Q4 2021 and bottomed at $1.5 million in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.93 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.06 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	1.84 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	912.74 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	215.33 Mn
10	Adagene	310.54 Mn	310.54 Mn	-	153,025.00

Download Data